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We assessed the impact of 10-valent and 13-valent 
pneumococcal vaccines (PCV10 and PCV13), which 
were introduced in Germany in 2009, on the incidence 
of meningitis and non-meningitis invasive pneumo-
coccal disease (IPD) in children aged under 16 years 
in a population previously vaccinated with a seven-
valent vaccine (PCV7). Surveillance of IPD (isolation of 
Streptococcus pneumonia from a normally sterile body 
site) is based on data from two independent reporting 
sources: hospitals and laboratories. IPD incidence was 
estimated by capture–recapture analysis. Incidence 
rate ratios (IRRs) were calculated for 2009 and 2012, 
thus comparing pre- and post-PCV10 and PCV13 data. 
IPD incidence caused by serotypes included in PCV13 
decreased in all age and diagnosis groups. A rise in 
non-vaccine serotype incidence was seen only in chil-
dren aged under two years. The overall impact varied 
by age group and infection site: for meningitis IPD in 
children aged under 2, 2–4 and 5–15 years, incidence 
changed by 3% (95% CI: −31 to 52), −60% (95% CI: −81 
to −17) and −9% (95% CI: −46 to 53), respectively. A 
more pronounced incidence reduction was observed 
for non-meningitis IPD: −30% (95% CI: −46 to −7), 
−39% (95% CI: −54 to −20) and −83% (95% CI: −89 
to −73) in children aged under 2, 2–4 and 5–15 years, 
respectively. A higher tropism of the additional sero-
types for non-meningitis IPD may be a potential expla-
nation. The heterogeneous findings emphasise the 
need for rigorous surveillance.
Introduction
The German Standing Committee on Vaccination 
(STIKO) included seven-valent pneumococcal conju-
gate vaccine (PCV7) in the infant vaccination calendar 
for all infants as of July 2006, with a 3 + 1 schedule 
given at 2, 3, 4 and 11–14 months of age [1]. Between 
2007 and 2009, vaccination with PCV7 prompted a 
sharp decrease in vaccine serotype incidence for all 
children aged under 16 years in Germany, whereas non-
vaccine serotype incidence rose. Both effects together 
resulted in a net reduction in IPD incidence [2]. Rising 
non-PCV7 serotype incidences were also observed in 
other countries: the most recent and comprehensive 
meta-analysis of the impact of PCV7 in different popu-
lations showed a reduction of about 50% for the inci-
dence of all IPD and about 60% for meningitis IPD [3]. 
After almost complete elimination of PCV7 serotypes in 
most populations, non-PCV7 serotypes accounted for a 
substantial proportion of remaining IPD cases, drawing 
attention to the need for higher-valent vaccines.
In Germany, the switch to higher-valent vaccines took 
place in April 2009 with the introduction of a 10-valent 
vaccine (PCV10) (market share in 2010–12: 9%) and in 
December 2009, when the 13-valent vaccine (PCV13) 
was introduced (market share in 2010–2012: 91%, inter-
nal sales figures provided by Pfizer Pharma GmbH). 
These higher-valent vaccines include all the serotypes 
in PCV7 and the most frequent non-PCV7 serotypes 
(PCV10: 1, 5, 7F; PCV13: 1, 3, 5, 6A, 7F and 19A). As 
73.6% of all IPD cases in children aged under 16 years 
in Germany from 2007 to 2009 were caused by PCV13 
serotypes [2] and given that the effectiveness of the 
six additional serotypes in PCV13 has been established 
using the Broome method [4], a considerable benefit 
from the switch to higher-valent pneumococcal vac-
cines was expected.
In Germany, sustained surveillance for IPD is based 
on two independent data sources: active surveillance 
in hospitals and passive sentinel surveillance through 
microbiological laboratories. The hospitals and labo-
ratories report on a voluntary basis, and there is an 
option for laboratories to send all pneumococcal iso-
lates from IPD cases for serotyping to the National 
Reference Center for Streptococci in Aachen free of 
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charge. Case ascertainment from these two independ-
ent sources allows underreporting to be corrected for 
by capture–recapture analysis.
Since vaccination coverage of pneumococcal conjugate 
vaccines has been above 85% since 2007, as estimated 
by internal sales figures provided by Pfizer Pharma 
GmbH, our data provide a basis to assess the impact 
of higher-valent vaccination (PCV10 and PCV13) up to 
three years after its introduction (2009 to 2012). Due to 
the limited market share of PCV10 (< 10%), we focused 
our research on the overall impact of both vaccines: 
PCV10 and PCV13. The aim of our study was to assess 
whether the incidence in PCV13 serotypes decreased 
during this period and whether there was a similar 




Hospital surveillance of IPD in children aged under 16 
years comprises all paediatric hospitals as well as pae-
diatric hospital wards in Germany (n > 400, response 
rate > 95%) [5]. It is managed by the German paediatric 
surveillance unit, Erhebungseinheit für seltene pädia-
trische Erkrankungen (ESPED). In the laboratory sen-
tinel surveillance, cases are reported through a web 
interface (PneumoWeb) hosted by the Robert Koch 
Institute [2,6-8].
Case definition
Cases are children under 16 years of age treated for IPD 
as inpatients in a paediatric hospital or paediatric ward 
in general hospitals in Germany. IPD was defined as 
Streptococcus pneumoniae being isolated from at least 
one culture of blood, cerebrospinal fluid or a sample 
from any other normally sterile body site. Isolates from 
middle ear fluid were not included. Both surveillance 
sources (hospitals and laboratories) applied the same 
case definition.
Definition of serotype coverage
Serotypes were grouped into vaccine type (VT) sero-
types, namely PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, 
23F) plus the additional serotypes included in PCV13 
(1, 3, 5, 6A, 7F, 19A) and into non-vaccine type (NVT) 
serotypes including all other serotypes. For cases for 
which serotype data were not available – because iso-
lates were not sent for serotyping – the same serotype 
distribution as for the serotyped cases was assumed.
Pneumococcal isolates were serotyped at the German 
National Reference Center for Streptococci, by Neufeld’s 
Quellung reaction using type and factor sera provided 
by the Statens Serum Institut, Copenhagen, Denmark.
Statistical analysis
Capture–recapture calculation (CRC) allows for adjust-
ment of incomplete reporting in (at least) two sources 
by identifying overlapping cases and applying Bayes’ 
probability theory to estimate the number of cases 
not included in either of the sources [9]. To avoid bias 
caused by small sample sizes, the Chapman estimator 
[10] was applied.
For the analysis of children too young to be vaccinated, 
we defined these as all children aged ≤2 months. 
Although children may already receive the first dose 
when two months-old, we aimed to take account of the 
tendency of belated vaccination in Germany [11] as well 
as of inaccuracy in the exact age of the children: Due 
to data protection, the day of birth was not provided 
in our study and it was therefore assumed that all chil-
dren were born on the first day of the month.
In this age subgroup ≤ 2 months, CRC was not possible 
since in 2012, all cases from the laboratory surveillance 
were included in the hospital surveillance, which ren-
ders CRC impossible. Therefore the analysis of the age 
group ≤ 2 months, and the comparison with children 
aged 3–23 months, was based on the cumulative num-
ber of cases in either source (ESPED and PneumoWeb).
The population denominator to convert the IPD case 
number estimates into incidence rates (per 100,000 
children) was based on age-specific (0–2, 2–4, 5–15 
and 0–15 years) population figures provided by the 
German Federal Statistical Office [12]. To assess the 
impact of the higher-valent pneumococcal conjugate 
vaccines (PCV10 and PCV13), we calculated incidence 
rate ratios (IRRs): we compared the incidence during 
years when PCV10 and PCV13 were exclusively used 
(2010, 2011 and 2012) with that in 2009, the last year 
of PCV7 use in Germany. A rate ratio of 1 indicates no 
effect of the switch from PCV7 to PCV10 and PCV13. 
Rate ratios less than 1 show a declining incidence of 
IPD, rate ratios greater than 1 indicate rising incidence. 
The 95% confidence intervals for the IRRs were cal-
culated using the method described by Armitage and 
Berry [13]. To compensate for chance fluctuations of 
the incidences in 2009 and 2012, we additionally cal-
culated the mean values of the two last years of PCV7 
vaccination (2008–09) as reference for the IRR calcula-
tion and compared them with the mean values of the 
last two years of PCV13 vaccination (2011–12).
All analyses were performed separately for meningitis 
and non-meningitis IPD cases, using SAS 9.2 software.
Results
Impact on vaccine-type incidence of invasive 
pneumococcal disease
From 2009 to 2012, there was a decrease in the inci-
dence of IPD caused by serotypes included in PCV13 
in all age groups for non-meningitis IPD, whereas a 
decrease for meningitis IPD could be observed in one 
age group (2–4 years) only. The absolute change in 
incidence was five- to 10-fold higher for non-meningitis 
IPD than meningitis IPD. The relative decrease ranged 
between 33% and 91%, depending on age and clinical 
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Table 1
Incidence and incidence changes of meningitis and non-meningitis invasive pneumococcal disease in children aged under 16 
years caused by serotypes in the 13-valent pneumococcal conjugate vaccine, based on capture–recapture calculationa, 
Germany, 2009 and 2012 
Age in years Diagnosis










incidence changeb  
% (95% CI) 
2009 vs 2012 
< 2
Meningitis 2.2 (1.3 to 3.1) 1.5 (1.0 to 1.9) −0.7 (−1.8 to  0.3) −33 (−62 to 18)
Non-meningitis 7.3 (4.6 to 10.1) 1.1 (0.6 to 1.7) −6.2 (−7.9 to −4.7) −85 (−91 to −74)
2–4
Meningitis 0.5 (0.3 to 0.7) 0.1 (0.05 to 0.07) −0.5 (−0.9 to −0.2) −91 (−99 to −30)
Non-meningitis 4.7 (2.8 to 6.7) 2.0 (0.6 to 3.3) −2.8 (−4.0 to −1.7) −58 (−71 to −40)
5–15
Meningitis 0.1 (0.1 to 0.2) 0.07 (0.05 to 0.10) −0.1 (−0.18 to 0.04) −50 (−81 to 36)
Non-meningitis 1.3 (0.5 to 2.0) 0.2 (0.1 to 0.3) −1.1 (−1.3 to −0.8) −84 (−90 to −73)
All < 16
Meningitis 0.4 (0.3 to 0.6) 0.2 (0.2 to 0.3) −0.2 (−0.4 to −0.1) −49 (−69 to −20)
Non-meningitis 2.6 (1.9 to 3.3) 0.7 (0.4 to 0.9) −2.0 (−2.3 to −1.6) −75 (−80 to −68)
CI: confidence interval; ESPED: German paediatric surveillance unit; IRR: incidence rate ratio; PneumoWeb: web interface for reporting of 
cases through laboratory sentinel surveillance.
Two-digits after the decimal point were used when necessary to avoid figures being rounded to 0.
Figures in bold indicate a statistically significant decrease or increase, since the 95% CI does not include 0.
a  Capture–recapture calculation was based on 231 vaccine-type invasive pneumococcal disease cases observed in two sources (without 
matches) – hospital (ESPED) and laboratory (PneumoWeb) surveillance – for 2009 and 2012 combined. For cases for whom serotype data 
were not available, the same serotype distribution as for the serotyped cases was assumed. The serotyping rate was 75%.
b  Calculated as 1 – IRR, as a percentage.
Table 2
Incidence and incidence changes of meningitis and non-meningitis invasive pneumococcal disease in children aged under 16 
years caused by serotypes not included in the 13-valent pneumococcal conjugate vaccine, based on capture–recapture 
calculationa, Germany, 2009 and 2012 
Age in years Diagnosis










incidence changeb  
% (95% CI) 
2009 vs 2012 
< 2
Meningitis 1.4 (0.9 to 2.0) 2.3 (1.5 to 3.0)  0.8 (−0.2 to 1.9)  59 (−10 to 82)
Non-meningitis 1.6 (1.0 to 2.2) 5.2 (2.6 to 7.8)  3.6 (2.2 to 5.1)  225 (101 to 428)
2–4
Meningitis 0.7 (0.4 to 1.0) 0.4 (0.3 to 0.5) −0.3 (−0.8 to 0.2) −39 (–74 to 42)
Non-meningitis 1.8 (1.1 to 2.5) 2.0 (0.6 to 3.3)  0.2 (−0.1 to 0.7)  11 (−73 to 29)
5–15
Meningitis 0.2 (0.1 to 0.3) 0.3 (0.2 to 0.4)  0.04 (−0.1 to 0.2)  17 (−18 to 37)
Non-meningitis 0.4 (0.2 to 0.7) 0.09 (0.04 to 0.13) −0.4 (−0.5 to −0.2) −79 (−91 to −54)
All < 16
Meningitis 0.5 (0.3 to 0.6) 0.5 (0.4 to 0.6)  0.1 (−0.1 to 0.3)  14 (−21 to 65)
Non-meningitis 0.8 (0.6 to 1.0) 1.0 (0.6 to 1.5)  0.3 (0.01 to 0.5)  33 (2 to 74)
CI: confidence interval; ESPED: German paediatric surveillance unit; IRR: incidence rate ratio; PneumoWeb: web interface for reporting of 
cases through laboratory sentinel surveillance. 
Two-digits after the decimal point were used when necessary to avoid figures being rounded to 0.
Figures in bold indicate a statistically significant decrease or increase, since the 95% CI does not include 0.
a  Capture–recapture calculation was based on 181 non-vaccine-type invasive pneumococcal disease cases observed in two sources (without 
matches) – hospital (ESPED) and laboratory (PneumoWeb) surveillance – for 2009 and 2012 combined. For cases for whom serotype data 
were not available, the same serotype distribution as for the serotyped cases was assumed. The serotyping rate was 75%.
b  Calculated as 1 – IRR, as a percentage. 
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Table 3





Last year of PCV7 
vaccination period
 
PCV10 and PCV13 vaccination period
2009 2010 2011 2012
Number of reported cases in 
the two surveillance sources:
ESPED; Pneumoweb
< 2 24; 15 30; 21 21; 11 29; 16
2–4 15; 7 16; 10 8; 7 8; 5
5–15 21; 9 9; 4 12; 10 14; 12
All < 16 60; 31 55; 35 41; 28 51; 33
Estimated number of cases 
by CRC (95% CI) 
< 2 49.0 (30.0 to 68.0) 55.8 (39.5 to 72.1) 51.8 (23.4 to 80.2) 50.0 (34.2 to 65.8)
2–4 24.6 (14.2 to 35.0) 30.2 (17.6 to 42.7) 23.0 (7.8 to 38.2) 9.8 (7.4 to 12.2)
5–15 30.4 (20.6 to 40.3) 24.0 (4.4 to 43.6) 22.8 (14.1 to 31.6) 26.9 (17.3 to 36.4)
All < 16 104.0 (80.2 to 127.9) 110.0 (81.6 to 138.4) 97.6 (64.3 to 131.0) 86.7 (68.0 to 105.3)
Estimated incidence by CRC
per 100,000 children (95% CI)
< 2 3.6 (2.2 to 5.0) 4.1 (2.9 to 5.3) 3.8 (1.7 to 5.9) 3.7 (2.4 to 4.5)
2–4 1.2 (0.7 to 1.7) 1.5 (0.9 to 2.1) 1.1 (0.4 to 1.9) 0.5 (0.4 to 0.6)
5–15 0.4 (0.2 to 0.5) 0.3 (0.1 to 0.5) 0.3 (0.2 to 0.4) 0.3 (0.2 to 0.4)





1.14 (0.78 to 1.68) 1.06 (0.72 to 1.57) 1.03 (0.69 to 1.52)
2–4 1.22 (0.72 to 2.09) 0.93 (0.53 to 1.65) 0.40 (0.19 to 0.83)
5–15 0.80 (0.47 to 1.36) 0.77 (0.44 to 1.32) 0.91 (0.54 to 1.53)
All < 16 1.06 (0.82 to 1.39) 0.95 (0.72 to 1.26) 0.85 (0.64 to 1.13)
CI: confidence interval; CRC: capture–recapture calculation; ESPED: German paediatric surveillance unit; IRR: incidence rate ratio; NA: 
not applicable; PCV: pneumococcal conjugate vaccine; PneumoWeb: web interface for reporting of cases through laboratory sentinel 
surveillance.
a  With reference to the incidence rate in 2009. IRRs with 95% CIs excluding 1 are shown in bold.
Table 4
Non-meningitis invasive pneumococcal disease in children aged under 16 years: reported cases, incidence estimates and rate 
ratios, Germany, 2009–12
Value Age group in years
Last year of PCV7 
vaccination period PCV10 and PCV13 vaccination period
2009 2010 2011 2012
Number of reported 
cases in the two 
surveillance sources:
ESPED; Pneumoweb
< 2 42; 33 35; 31 21; 16 24; 23
2–4 47; 30 22; 19 27; 16 21; 14
5–15 32; 25 23; 28 21; 29 10; 8
All < 16 121; 88 80; 78 69; 61 55; 45
Estimated number of 
cases by CRC (95% CI) 
< 2 120.8 (75.6 to 166.1) 127.0 (68.8 to 185.2) 61.3 (29.7 to 93.0) 84.7 (42.3 to 127.1)
2–4 134.3 (80.3 to 188.2) 75.7 (34.8 to 116.5) 67.0 (35.7 to 98.3) 81.5 (25.5 to 137.5)
5–15 142.0 (58.0 to 226.0) 115.0 (48.7 to 181.3) 109.0 (46.8 to 171.2) 23.8 (10.9 to 36.6)
All < 16 397.1 (287.5 to 506.8) 317.7 (220.4 to 414.9) 237.3 (160.9 to 313.8) 190.0 (118.5 to 261.4)
Estimated incidence by 
CRC per 100,000 children 
(95% CI)
< 2 8.9 (5.6 to 12.3) 9.4 (5.1 to 13.7) 4.6 (2.2 to 6.9) 6.3 (3.1 to 9.4)
2–4 6.5 (3.9 to 9.2) 3.7 (1.7 to 5.7) 3.3 (1.7 to 4.8) 4.0 (1.2 to 6.4)
5–15 1.7 (0.7 to 2.7) 1.4 (0.6 to 2.2) 1.3 (0.6 to 2.1) 0.3 (0.1 to 0.4)





1.05 (0.82 to 1.35) 0.51 (0.37 to 0.69) 0.70 (0.53 to 0.93)
2–4 0.56 (0.42 to 0.75) 0.50 (0.37 to 0.67) 0.61 (0.46 to 0.80)
5–15 0.82 (0.64 to 1.05) 0.78 (0.61 to 1.01) 0.17 (0.11 to 0.27)
All < 16 0.81 (0.70 to 0.93) 0.61 (0.52 to 0.71) 0.50 (0.42 to 0.60)
CI: confidence interval; CRC: capture–recapture calculation; ESPED: German paediatric surveillance unit; IRR: incidence rate ratio; NA: 
not applicable; PCV: pneumococcal conjugate vaccine; PneumoWeb: web interface for reporting of cases through laboratory sentinel 
surveillance.
a  With reference to the incidence rate in 2009. IRRs with 95% CIs excluding 1 are shown in bold.
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presentation. The relative incidence decrease was low-
est (and not statistically significant) for meningitis IPD 
in the youngest age group, i.e. under two years (Table 
1).
In the under two years age group, a distinction needs to 
be made between children too young to be vaccinated 
(≤ 2 months) and those for whom the universal vaccina-
tion recommendation applies (3–23 months). In 2009, 
VT meningitis IPD cases aged ≤ 2 months accounted for 
5 of 19 VT cases in children aged under two years com-
pared with 9 of 14 cases in 2012. Among the nine 2012 
cases, five were due to serotype 7F. The high propor-
tion of 7F among these cases contrasts with the vac-
cine serotype distribution in all older age groups (> 2 
months), among whom serotype 7F had almost van-
ished (one case in the age group 3–23 months, one 
among children aged 2–15 years). The age group ≤ 2 
months was the only group in which VT meningitis IPD 
increased. In children aged 3–23 months, the number 
of meningitis cases with PCV13 serotypes decreased 
from 14 cases in 2009 to five in 2012.
Regarding non-meningitis IPD cases, in children 
aged ≤ 2 months, the number of VT IPD cases decreased 
from six (2009) to three (2012); in children aged 3–23 
months, the number of VT IPD cases fell from 47 to five.
Impact on non-vaccine-type invasive 
pneumococcal disease incidence
For non-PCV13 vaccine serotypes, an inconsistent pat-
tern was observed. There was an increase in the inci-
dence of NVT serotypes in children aged under two 
years (for children ≤ 2 months as well as for those aged 
3–23 months), which was statistically significant for 
non-meningitis IPD but not for meningitis IPD. In older 
age groups, the incidence of NVT IPD increased in some 
age groups while decreasing in others. There was a 
statistically significant decrease of non-meningitis IPD 
in 5–15 year-old children (Table 2).
Impact on overall (vaccine type and non-
vaccine type) incidence of meningitis and non-
meningitis invasive pneumococcal disease
The impact of PCV13 on the overall number and inci-
dence of meningitis IPD cases is shown in Table 3. 
While barely no change or even a slight rise in the num-
ber of meningitis IPD cases is shown in the laboratory 
source PneumoWeb, the hospital data source showed 
a decrease in the number of these cases among chil-
dren aged two years or older, but also no decrease in 
those aged under two years. This was confirmed in the 
capture–recapture analysis: some decrease in older 
age groups (two years and above) and virtually no inci-
dence reduction in children aged under two years. The 
IRRs suggest an incidence reduction, which was sig-
nificant for the 2–4 years age group only: −60% (95% 
CI: −81 to −17). For children aged 5–15 years, CRC inci-
dence changed by −9% (95% CI: −46 to 53). For children 
aged under two years, the change was 3% (95% CI: −31 
to 52).
In order to disentangle the changes in children too 
young to be vaccinated (≤ 2 months) and those for whom 
the universal vaccination recommendation applies 
(3–23 months), we report data for each subgroup: for 
children ≤  2 months, the incidence of meningitis IPD 
Table 5
Sensitivity analysis: incidence rate ratios of meningitis and 
non-meningitis invasive pneumococcal disease in children 
aged under 16 years (mean of 2011–12 vs mean of 2008–09), 
based on capture–recapture calculationa, Germany 
Age group 
in years
IRR: average of 2011–12
vs average of 2008–09 (95% CI)
Meningitis IPD Non-meningitis IPD
< 2 1.06 (0.80 to 1.40) 0.58 (0.47 to 0.71)
2–4 0.56 (0.36 to 0.87) 0.76 (0.61 to 0.94)
5–15 1.16 (0.77 to 1.72) 0.53 (0.43 to 0.65)
All < 16 0.95 (0.78 to 1.16) 0.65 (0.58 to 0.73)
CI: confidence interval; ESPED: German paediatric surveillance 
unit; IPD: invasive pneumococcal disease; IRR: incidence rate 
ratio; PneumoWeb: web interface for reporting of cases through 
laboratory sentinel surveillance. 
95% CIs not including 1 are shown in bold.
a  Capture–recapture calculation was based on 798 IPD cases 
observed in two sources (without matches) – hospital (ESPED) 
and laboratory (PneumoWeb) surveillance – for 2008, 2009, 
2011 and 2012 combined. 
Table 6
Absolute number and percentage of vaccine type 
serotypesa in paediatric (< 16 years) invasive 


















IPD cases by 
any serotype  
(95% CI) 
< 2 30 61 (48 to 75) 99 82 (74 to 90)
2–4 11 43 (28 to 64) 98 73 (64 to 82)
5–15 12 44 (26 to 58) 107 75 (65 to 85)
All < 16 53 49 (40 to 59) 304 77 (72 to 82)
CI: confidence interval; ESPED: German paediatric surveillance 
unit; IPD: invasive pneumococcal disease; PneumoWeb: web 
interface for reporting of cases through laboratory sentinel 
surveillance; VT: vaccine type. 
a  VT serotypes were all serotypes included in the 13-valent 
pneumococcal vaccine (PCV13), i.e. seven-valent pneumococcal 
vaccine (PCV7) serotypes (4, 6B, 9V, 14, 18C, 19F, 23F) plus an 
additional six serotypes (1, 3, 5, 6A, 7F, 19A).
b  Numbers according to capture–recapture calculation based 
on 257 invasive pneumococcal disease cases observed in two 
sources (without matches) – hospital (ESPED) and laboratory 
(PneumoWeb) surveillance  – for 2009. For cases for whom 
serotype data were not available, the same serotype distribution 
as for the serotyped cases was assumed. The serotyping rate 
was 75%.
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increased from 1.1 per 100,000 children in 2009 to 1.5 
per 100,000 in 2012. In children aged 3–23 months, it 
was 2.1/100,000 in 2009 and 2.2/100,000 in 2012.
A different pattern was observed for non-meningitis 
IPD cases (Table 4). The numbers in each data source 
showed a decrease from 2009 to 2012 (with some fluc-
tuations in 2010 and 2011). This decrease was con-
firmed in the capture–recapture analysis: a statistically 
significant reduction in incidence of non-meningitis 
IPD was observed in all age groups, except for chil-
dren ≤ 2 months, in whom incidence was 1.4/100,000 in 
both 2009 and 2012. For children aged under 2 years, 
the decrease was −30% (95% CI: −46 to −7). For older 
children aged 2–4  and 5–15 years, the decrease was 
−39% (95% CI: −54 to −20) and −83% (95% CI: −89 to 
−73), respectively.
In order to confirm that the observed results did not 
reflect an artefact resulting from the use of CRC, we 
also assessed the changes in case numbers and inci-
dence rates between 2009 and 2012 solely based on 
the observed number of cases reported in both sur-
veillance sources (counting cases observed in both 
sources only once): the changes (IRRs) related to the 
introduction of PCV10 and PCV13 were almost identical 
to those based on CRCs.
We also calculated CRC-based IRRs for the two-year 
periods 2008–09 and 2011–12 (Table 5), which yielded 
very similar results to our comparison of 2012 with 
2009. Only the decrease of non-meningitis IPD in 5–15 
year-old children (1 − IRR = −46% (95% CI: −57 to −35) 
was outside the 95% CIs of the corresponding result in 
Table 4 (1 − IRR: −83% (95% CI: −89 to −73) and thus 
significantly and substantially smaller in the analysis 
which compared 2008-09 to 2011-12, reflecting the 
sharp decrease in incidence in this age group in 2012.
The percentages of VT serotypes in IPD cases among 
children aged under 16 years in 2009 is shown in Table 
6. This percentage was smaller for meningitis IPD than 
for non-meningitis IPD in all age groups. The VT sero-
types in 2009 consisted mainly (84%, 300/357) of the 
six serotypes (1, 3, 5, 6A, 7F, 19A) that were not con-
tained in PCV7.
Discussion
For non-meningitis IPD, the introduction of PCV10 and 
PCV13 prompted a marked decrease in the incidence 
of IPD cases caused by PCV13 serotypes. This was not 
confined to the PCV13-vaccinated cohorts aged under 
two years but was almost as pronounced in those older 
than two years. An increasing incidence of IPD cases 
caused by NVT serotypes was solely observed in chil-
dren under two years-old. This NVT increase, however, 
was smaller than the VT decrease, so that an overall 
decrease of non-meningitis IPD (regardless of sero-
type) was observed in all age groups.
In contrast, for meningitis IPD, we did not observe a 
decrease in the VT incidence in children aged under two 
years, nor in the oldest age group (5–15 years). 
Therefore, the overall incidence decrease (regardless 
of serotype) was limited to 2–4 year-old children.
The clear decrease of PCV13 serotypes in non-meningi-
tis IPD in children under two years-old reflects the high 
effectiveness of PCV13 against the six additional sero-
types (1, 3, 5, 6A, 7F and 19A) not contained in PCV7, as 
demonstrated by Miller et al. [4]. The additional effect 
in older age groups not vaccinated with PCV10 or PCV13 
indicates herd protection.
In accordance with the previously reported increase in 
non-PCV7 serotypes after the introduction of PCV7 [3], 
we observed an increase of non-PCV13 serotypes three 
years after the introduction of PCV13. In our data, this 
early increase was confined to the vaccinated cohorts 
aged under two years, where it was substantial in non-
meningitis IPD, but did not reach statistical significance 
in meningitis IPD. From a clinical and public health 
perspective, the overall net impact on IPD incidence 
(regardless of VT or NVT serotype) is most relevant. 
While there was an overall decrease of non-meningitis 
IPD incidence in all age groups, the decrease of menin-
gitis IPD incidence was confined to children in the age 
group 2–4 years. At first glance, this differential impact 
is surprising. A likely explanation is the lower propor-
tion of PCV13 serotypes among meningitis IPD cases 
(49%; 95% CI: 40 to 59) than among non-meningitis IPD 
cases (77%; 95% CI: 72 to 82) in 2009 when PCV13 was 
introduced in Germany, meaning that a larger propor-
tion of non-meningitis IPD was preventable by PCV13. 
The clear decrease in the non-meningitis IPD incidence 
(regardless of serotype) might theoretically be due to 
less frequent blood culturing. However, previous find-
ings rather suggested increasing blood culturing rates 
since the introduction of infant pneumococcal vaccina-
tion in Germany [2].
Although chance might be another explanation, given 
the wide 95% CIs of the IRRs, biological explanations 
related to the tropism of different pneumococcal sero-
types appear more likely: German data collected in 
1997–98 (during the pre-vaccination period) showed 
an about equal incidence of meningitis and non-men-
ingitis IPD for serotypes 6A, 7F and 19A, whereas the 
incidence of serotypes 1, 3 and 5 was significantly 
higher in non-meningitis than in meningitis IPD [6]. A 
similar pattern was observed after the introduction of 
PCV in 2007 (data not shown). A literature review pub-
lished in 2013, with observations from other countries, 
addressed the issue of tropism of different pneumococ-
cal serotypes: serotypes 1, 19A and 3 were identified 
as predominant for pneumococcal pneumonia but not 
for meningitis IPD during the post-PCV7 period [14]. 
A recent paper from India, not included in the review, 
reported that serotypes 1, 5 and 7F (three of the six 
additional serotypes in PCV13) caused more pneumo-
nia than meningitis [15].
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For children aged under two years, the decreased inci-
dence of meningitis IPD was not only less than that of 
non-meningitis IPD in this age group, but no decrease 
was observed at all. One explanation might be an 
increase in the number of cases caused by NVT sero-
types. However, this increase was not statistically 
significant. Notable was an increase in the number of 
cases caused by VT serotypes in children ≤  2 months-
old, in particular serotype 7F. Children ≤  2 months of 
age are too young to be vaccinated, according to the 
German vaccination schedule, and can thus only indi-
rectly benefit from vaccination through herd protec-
tion. The reason for the absence of herd protection in 
this age group in 2012 is unclear.
There are limited data on the impact of PCV13 on the 
incidence of IPD in previously PCV7-vaccinated popu-
lations and distinctions between non-meningitis and 
meningitis IPD are only made in one study: for England 
and Wales, where PCV13 replaced PCV7 in April 2010, 
Miller et al. reported a 50% reduction in the number 
of cases caused by PCV13 serotypes (for meningitis 
and non-meningitis IPD combined) in children aged 
under two years after one year of PCV13 use [4]. In a 
multicentre study from eight hospitals in the United 
States (where PCV13 was used as of March 2010), IPD 
cases per total admissions were analysed, comparing 
the mean of 2007–09 with the number of cases in 2011. 
A 57% decrease in PCV13 serotypes and a 42% reduc-
tion in IPD cases per total admissions for children aged 
under five years was reported. Meningitis cases were 
reduced the least [16]. Data from Denmark, where 
PCV13 was introduced in April 2010, show a decrease 
of IPD incidence (regardless of clinical entity) by about 
a third in children under two years-old [17].
A strength of our study is the separate analysis of men-
ingitis and non-meningitis IPD cases. Differences in 
incidence of meningitis and non-meningitis IPD show 
the importance of separate data analysis according 
to clinical entity. The high proportion of meningitis 
among incident IPD in children aged under 16 years in 
Germany (26% (628/2,394) for 2007–12) was similar 
to the proportion in Denmark (20%) [18], but much 
higher than the proportion in the United Kingdom (6%) 
[19]. For countries with high blood culturing rates, and 
therefore a high proportion of non-meningitis IPD, 
aggregate estimates of PCV impact on IPD may mask 
a differential effect on meningitis IPD. Meningitis IPD, 
however, has a higher clinical relevance and public 
health impact because case fatality and sequelae rates 
are about fourfold higher than for non-meningitis IPD 
[6].
Separate analysis (and publication) of meningitis and 
non-meningitis IPD cases is also useful for comparison 
of international data, since meningitis IPD incidence is 
less likely to be affected by ascertainment bias. This 
is demonstrated by similar incidence rates in differ-
ent countries [20], while non-meningitis IPD incidence 
is dependent on blood culturing practices for children 
with fever – practices that differ between countries 
and can change over time [21].
Another strength of our data is the use of two inde-
pendent data sources, which allows us to correct for 
underreporting by CRC.
A potential limitation is the comparison of two one-year 
periods (2009 and 2012, three years after the introduc-
tion of PCV7 and PCV13, respectively). We chose these 
time periods to include two cohorts of children under 
two years-old, who could have been fully vaccinated 
with either PCV7 or PCV13. To reduce random variabil-
ity due to small numbers when comparing two one-year 
periods only, we also compared 2008–09 with 2011–
12. This yielded almost identical results, rendering 
chance a less likely explanation of our findings.
A limitiation of our data is the confinement of our anal-
ysis to children aged under 16 years.
It might also be argued that the strength of the effect 
of higher-valent pneumococcal vaccines might be 
underestimated as PCV10 was already introduced in 
Germany in April 2009 and PCV13 in December 2009. 
Both higher-valent vaccines were used, when PCV7 was 
still on the market. The market shares of the higher-
valent vaccines in 2009, however, were small (PCV10: 
21%; PCV13: 7%) and PCV7 was the predominantly 
used vaccine during 2009.
An overestimation of the impact of PCV13 is possible 
as well because of a potential increase in IPD incidence 
due to the influenza A(H1N1)pdm09 pandemic in 2009, 
which had reached its peak during calendar weeks 
45–48 of 2009 [2,22,23]. Again, our two-year period 
comparison (2008–09 vs 2011–12) did not suggest bias 
due to picking 2009 as the base year for comparisons.
In a commentary, Katharine O’Brian described pneu-
mococcal disease impact evaluations as a ‘messy 
affair’ and called for ‘epidemiologic rigor’ [24]. The het-
erogeneous findings in our study, once again, point to 
the importance of sustained surveillance of IPD and the 
need for thorough and detailed analysis disentangling 
the vaccine impact on different clinical entities.
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